KDR and cholangiocarcinoma: Previously, the expressions of VEGF and VEGF receptor 2, i.e., kinase domain-containing receptor (KDR), were analyzed using the immunohistochemical assay in 60 cases of cholangiocarcinoma tissues and 40 cases of normal bile duct epithelial tissues.